Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea

CompletedOBSERVATIONAL
Enrollment

11,385

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Ulcerative Colitis
Interventions
OTHER

PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)

"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY